PHC-102 is 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors.
The product consist of a CAIX ligand derived from acetazolamide, a linker and a peptide 99mTC chelator.
CAIX is a validated target which is expressed in the majority of RCC patients, but also in a proportion of patients with other malignancies (e.g., ~30% of patients with CRC).
In preclinical studies, PHC-102 demonstrated high tumor uptake and favorable tumor-to-kidney ratios of up to 3.
This favourable selectivity may allow imaging of tumors in the kidney and distant sites at earlier time points than commonly possible with antibody-based products.
The product has recently entered phase 1 clinical development in patients with renal cell carcinoma.
Krall (2016) J. Nucl. Med.; 57; 943-9
Krall (2014) Chem Sci (Camb).; 5; 3640–3644.